Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Luo, G. Fonarow, Steven Lippmann, Xiaojuan Mi, P. Heidenreich, C. Yancy, Melissa Greiner, B. Hammill, N. Hardy, S. Turner, W. Laskey, L. Curtis, Adrian Hernandez, R. Mentz, Emily O'Brien (2017)
Early Adoption of Sacubitril/Valsartan for Patients With Heart Failure With Reduced Ejection Fraction: Insights From Get With the Guidelines-Heart Failure (GWTG-HF).JACC. Heart failure, 5 4
T. Gaziano, G. Fonarow, B. Claggett, Wing Chan, C. Deschaseaux-Voinet, S. Turner, J. Rouleau, M. Zile, J. McMurray, S. Solomon (2016)
Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.JAMA cardiology, 1 6
S. Greene, J. Butler, N. Albert, A. DeVore, P. Sharma, Carol Duffy, C. Hill, K. Mccague, Xiaojuan Mi, J. Patterson, J. Spertus, L. Thomas, Fredonia Williams, Adrian Hernandez, G. Fonarow (2018)
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.Journal of the American College of Cardiology, 72 4
N. Albert, C. Yancy, L. Liang, Xin Zhao, Adrian Hernandez, E. Peterson, C. Cannon, G. Fonarow (2009)
Use of aldosterone antagonists in heart failure.JAMA, 302 15
S. Dusetzina, N. Keating, H. Huskamp (2019)
Proposals to Redesign Medicare Part D - Easing the Burden of Rising Drug Prices.The New England journal of medicine
Alexander Sandhu, D. Ollendorf, R. Chapman, S. Pearson, P. Heidenreich (2016)
Cost-Effectiveness of SacubitrilValsartan in Patients With Heart Failure With Reduced Ejection FractionAnnals of Internal Medicine, 165
A. DeVore, C. Hill, L. Thomas, P. Sharma, N. Albert, J. Butler, J. Patterson, J. Spertus, Fredonia Williams, Carol Duffy, K. Mccague, Adrian Hernandez, G. Fonarow (2018)
Patient, Provider, and Practice Characteristics Associated With Sacubitril/Valsartan Use in the United StatesCirculation: Heart Failure, 11
J. McMurray, S. Solomon, S. Inzucchi, L. Køber, M. Kosiborod, F. Martinez, P. Ponikowski, M. Sabatine, I. Anand, J. Bělohlávek, M. Böhm, C. Chiang, V. Chopra, R. Boer, Akshay Desai, M. Diez, J. Drożdż, A. Dukát, J. Ge, J. Howlett, T. Katova, M. Kitakaze, C. Ljungman, B. Merkely, J. Nicolau, E. O’Meara, M. Petrie, P. Vinh, M. Schou, S. Tereshchenko, S. Verma, C. Held, D. DeMets, K. Docherty, P. Jhund, O. Bengtsson, M. Sjöstrand, A. Langkilde, Modele Ogunniyi (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.The New England journal of medicine
Yancy (2016)
2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.Circulation, 134
A. Kansal, M. Cowie, A. Kielhorn, S. Krotneva, A. Tafazzoli, Ying Zheng, N. Yurgin (2016)
Cost‐Effectiveness of Ivabradine for Heart Failure in the United StatesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 5
C. DeJong, Dhruv Kazi, R. Dudley, Randi Chen, Chien-Wen Tseng (2019)
Assessment of National Coverage and Out-of-Pocket Costs for Sacubitril/Valsartan Under Medicare Part D.JAMA cardiology
K. Parikh, Steven Lippmann, Melissa Greiner, P. Heidenreich, C. Yancy, G. Fonarow, Adrian Hernandez (2017)
Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization: Findings From the GWTG-HF Registry (Get With The Guidelines-Heart Failure).Circulation, 135 21
N. Albert, J. Swindle, E. Buysman, Chun‐Lan Chang (2019)
Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin‐Converting Enzyme Inhibitor or Angiotensin‐Receptor Blocker in a Retrospective Analysis of Patients With Heart FailureJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 8
R. Frank, L. Nichols (2019)
Medicare Drug-Price Negotiation - Why Now . . . and How.The New England journal of medicine
Key PointsQuestionWhat are the patterns of use and associated costs of sacubitril/valsartan and ivabradine for Medicare Part D and Medicaid? FindingsIn this US nationwide claims-based study, the number of Medicare beneficiaries prescribed sacubitril/valsartan increased from 35 423 to 90 606 (156% increase from 2016 to 2017). Medicare beneficiaries prescribed ivabradine increased from 15 856 to 23 213 (46% increase), the annual Medicare per-beneficiary spending on sacubitril/valsartan and ivabradine was $2512 and $2400, and parallel trends in use patterns and spending were observed among Medicaid beneficiaries. MeaningCurrent use of sacubitril/valsartan and ivabradine is increasing, but ongoing efforts are needed to promote high-value care, while improving affordability and access to established and emerging heart failure therapies.
JAMA Cardiology – American Medical Association
Published: Mar 18, 2020
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.